Ipilimumab/nivolumabImmune related myositis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1827卷 / 1期

关键词：

D O I：

10.1007/s40278-020-84940-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：185 / 185

相关论文

共 50 条

[41] Ipilimumab/nivolumabImmune checkpoint inhibitor overlap syndrome : case report
Reactions Weekly, 2025, 2052 (1) : 225 - 225
[42] Ipilimumab/nivolumabImmune related dermatitis, diverticulitis and pneumonitis: 3 case reports
Reactions Weekly, 2021, 1858 (1) : 214 - 214
[43] NivolumabImmune related pneumonitis: case report
Reactions Weekly, 2021, 1838 (1) : 399 - 399
[44] NivolumabImmune related Colitis: case report
Reactions Weekly, 2018, 1705 (1) : 246 - 246
[45] NivolumabImmune related eczema: case report
Reactions Weekly, 2017, 1659 (1) : 217 - 217
[46] NivolumabImmune-related meningoencephalitis: case report
Reactions Weekly, 2021, 1864 (1) : 307 - 307
[47] Ipilimumab/pembrolizumabMyasthenia gravis and myositis: case report
Reactions Weekly, 2018, 1728 (1) : 201 - 201
[48] Ipilimumab/nivolumabLack of efficacy and myositis: case report
Reactions Weekly, 2023, 1957 (1) : 313 - 313
[49] Ipilimumab/nivolumabAcute myocarditis and myositis: case report
Reactions Weekly, 2017, 1654 (1) : 194 - 194
[50] Ipilimumab/nivolumab/prednisoloneImmune-related myositis and lack of efficacy: case report
Reactions Weekly, 2023, 1986 (1) : 227 - 227

← 1 2 3 4 5 →